CP and viral infectious disease: SARS‐CoV‐2‐targeting blood‐derived product therapies, such as COVID‐19 CP, COVID‐HIG, and neutralizing IgG (recombinant), are considered passive immunotherapies that enable immediate control of viral infection in the short term, emphasizing the importance of early administration for improved efficacy.